Michael Rider - ResMed Chief Secretary
| RMD Stock | USD 256.29 2.62 1.01% |
Executive
Michael Rider is Chief Secretary of ResMed Inc
| Age | 68 |
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
Michael Rider Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Rider against ResMed stock is an integral part of due diligence when investing in ResMed. Michael Rider insider activity provides valuable insight into whether ResMed is net buyers or sellers over its current business cycle. Note, ResMed insiders must abide by specific rules, including filing SEC forms every time they buy or sell ResMed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Rider over a year ago Disposition of tradable shares by Michael Rider of ResMed at 248.91 subject to Rule 16b-3 | ||
Michael Rider over a year ago Disposition of 173 shares by Michael Rider of ResMed subject to Rule 16b-3 | ||
Michael Rider over a year ago Disposition of 200 shares by Michael Rider of ResMed at 173.25 subject to Rule 16b-3 |
ResMed Management Efficiency
The company has Return on Asset of 0.1475 % which means that on every $100 spent on assets, it made $0.1475 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2568 %, implying that it generated $0.2568 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.28, whereas Return On Capital Employed is forecasted to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 121.7 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Claire Mulhearn | Insmed Inc | N/A | |
| Claire Dickson | Haleon plc | N/A | |
| George Newcomb | GE HealthCare Technologies | 59 | |
| Namrata Patel | Haleon plc | 60 | |
| Andrea Spannheimer | IQVIA Holdings | N/A | |
| Marc Gueronniere | Mettler Toledo International | 62 | |
| Philip Binns | Agilent Technologies | N/A | |
| Matt Sims | Cardinal Health | N/A | |
| Shawn Bevec | Becton Dickinson and | N/A | |
| Susan GrahamBryce | Mettler Toledo International | 50 | |
| Japan Mehta | Humana Inc | 45 | |
| August Specht | Agilent Technologies | N/A | |
| Denise Fleming | Becton Dickinson and | 56 | |
| William Shrank | Humana Inc | 49 | |
| Rana Strellis | GE HealthCare Technologies | N/A | |
| Joseph Ventura | Humana Inc | 49 | |
| Neil Hughes | Insmed Inc | N/A | |
| Tejas Savant | Agilent Technologies | N/A | |
| Christie Camelio | Insmed Inc | N/A | |
| Jeffrey MD | IQVIA Holdings | N/A | |
| Val Pitteroff | Cardinal Health | N/A | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.15 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Secretary | ||
| Vered Keisar, Chief Officer | ||
| Carlos MD, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Michael Fliss, Chief Officer | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Constance Bienfait, Director Relations | ||
| Hemanth Reddy, Chief Officer | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Dawn Haake, Chief Officer | ||
| Justin Leong, President – Asia and Latin America | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Sallilyn Schwartz, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer | ||
| Alastair Robertson, Chief Officer | ||
| Todd Friedman, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 36.22 B | ||||
| Shares Outstanding | 145.68 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 68.19 % | ||||
| Number Of Shares Shorted | 11.12 M | ||||
| Price To Earning | 73.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Health Care Equipment & Supplies sector continue expanding? Could ResMed diversify its offerings? Factors like these will boost the valuation of ResMed. Anticipated expansion of ResMed directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ResMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.145 | Dividend Share 2.26 | Earnings Share 10.1 | Revenue Per Share | Quarterly Revenue Growth 0.11 |
ResMed Inc's market price often diverges from its book value, the accounting figure shown on ResMed's balance sheet. Smart investors calculate ResMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ResMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ResMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ResMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.